Paradoxically, the genetic ablation of IL-33 leads to asthma and cardiac hypertrophy [74]; at HNLD and LD10 doses in this study, cardiac IL-33 was still significantly decreased at day 7, suggesting a long-term impact warranting further elucidation. The gene discussed is IL33; the disease is cardiac hypertrophy.